Bio-Thera Out-Licenses Golimumab To Russia And CIS

Represents Foray Into ‘Important Market’

With a number of next wave candidates in its pipeline, China’s Bio-Thera Solutions has licensed one of them, golimumab, to Russian player Pharmapark, ahead of a global Phase III trial later this year.

Russia_Night
Pharmapark will leverage its strong local presence, sales and marketing capabilities, Bio-Thera said • Source: Shutterstock

Bio-Thera Solutions Ltd. has signed its first partnership to establish a presence in Russia, agreeing to out-license exclusive rights for its biosimilar Simponi (golimumab) candidate, BAT2506, in Russia and the Commonwealth and Indepdenent States to local player Pharmapark.

The Chinese firm says it is to begin a global Phase III study for BAT2506 in patients with active psoriatic...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.